Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 83.12

-2.1%

Jan 30 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mlkr who wrote (2701)	2/24/2010 11:53:13 AM
From: Jibacoa	Read Replies (1) of 3722

Yes, XNPT tried to bounce up from the DG of Feb 18 <g> The FDA said that questions remained on the NDA for XP13512, (Horizon) or gabapentin enacarbil for treating Restless Leg Syndorme, that precluded approval on its current form.<g> Horizon is been developed in conjunction with GSK and a version of gabapentin had already been approved by the FDA for the treatment of epilepsy. In 2008 XNPT completed a PIIa of XP13512 for the management of post-herpetic neuralgia. XNPT has a pretty good cash position, as of Dec2009, it had around $144M. But after the letter from the FDA several firms downgraded the stock last week and it found resistance on Monday at the $10.14 as it attempted to close some of its DG <g> Today StockPreacher issued an "StockAlert", which I haven't read.<g> XNPT has 3Qs of significant lower revenues and the results for the 1stQ(March)aren't expected to show a good comparison since last Yr. the 1stQ results were good.<g> Today the stock is showing some support at the $8 level and resistance at the $8.15 (presently trading support at $7.98 as I am writing <g>) Volume is already > its ADV. bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next